Mitoquinone Mesylate

Phase 2Small molecule

Mitoquinone Mesylate is one of 71 small molecule programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Alcoholic Fatty Liver DiseaseActive, not recruiting

Hepatitis CActive, not recruiting

Non-Alcoholic Fatty Liver DiseasePhase 2

Active, not recruiting

Hepatitis CPhase 2

Active, not recruiting

Competition

Competitive Landscape

306 competitors in Hepatitis C

#DrugCompanyPhaseTrials

Gocovri

GGrupo Espanol de Tumores Neuroendocrinos

Phase 3

2 2

TMC435

Johnson & Johnson

Phase 3

14 3

Thymalfasin

SSciClone Pharmaceuticals

Phase 3

1 4

Ledipasvir

Johnson & Johnson

Phase 3

3 5

PEG-IFN Alfa-2a

Roche

Phase 3

2 6

Pegylated Interferon Lambda

Bristol-Myers Squibb

Phase 3

2 7

Peginterferon Α-2a

Bristol-Myers Squibb

Phase 3

1 8

REBETOL

Merck & Co.

Phase 3

4 9

Pegylated Interferon Alfa-2a (PEG)

Roche

Phase 3

3 10

Interferon Alfacon-1

Astellas

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Vasodilation

NCT06027554

Clinical

Trials by Indication[1]

Vasodilation1 trial

The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

Recruiting·UUConn Health·Phase 2·NCT06027554·60 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)

Terminated·AAntipodean Pharmaceuticals, Inc.·Phase 2·NCT01167088·110 enrolled

Hepatitis C1 trial

Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C

Completed·AAntipodean Pharmaceuticals, Inc.·Phase 2·NCT00433108·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Mitoquinone Mesylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mitoquinone Mesylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mitoquinone Mesylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Antipodean Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAntipodean Pharmaceuticals, Inc.

Mitoquinone Mesylate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Vasodilation1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Hepatitis C1 trial

References

Drug Info

Quick Facts

Related News